Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIII-FS prophylaxis regimen study in pediatric hemophilia A
2014-005253-39Phase 4
- Sponsor
- Bayer
- Start
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of octocog alfa in hemophilia A (3 arms), sponsored by Bayer. Primary endpoint: Percentage of participants with fewer than 2 joint bleeds during the 9-month treatment period.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2014-005253-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005253-39.